Shares of Ascendis Pharma A/S (ASND) soared 5.4% in the pre-market session on Friday, riding on favorable analyst reports and better-than-expected quarterly earnings results.
Analysts from Bank of America Securities and Stifel Nicolaus reiterated their "Buy" ratings on the biopharmaceutical company, highlighting its strong growth prospects. Their positive views could have fueled investor optimism and contributed to the stock's surge.
Additionally, Ascendis Pharma reported a narrower-than-expected loss for the third quarter ended September 30. While the company posted a loss of €1.72 per share, it beat analysts' expectations of a €1.74 loss per share. The earnings beat, albeit modest, may have further boosted investor confidence in the company's performance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。